Crushed Prasugrel Tablets in Patients with STEMI Undergoing Primary Percutaneous Coronary Intervention the CRUSH Study

Journal of the American College of Cardiology

Volumn 67, Issue 17, 2016, Pages 1994-2004

  Rollini, Fabiana ^a   Franchi, Francesco ^a   Hu, Jenny ^a   Kureti, Megha ^a   Aggarwal, Niti ^a   Durairaj, Ashwin ^a   Park, Yongwhi ^a   Seawell, Michael ^a   Cox Alomar, Pedro ^a   Zenni, Martin M ^a   Guzman, Luis A ^a   Suryadevara, Siva ^a   Antoun, Patrick ^a   Bass, Theodore A ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

crushed tablet; pharmacodynamic; pharmacokinetic; platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MORPHINE; NITRIC ACID DERIVATIVE; ONDANSETRON; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; TABLET;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRUSHED PRASUGREL TABLET; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HEMATOLOGICAL PARAMETERS; HEMATURIA; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOLOGICAL PROCEDURES; PLATELET REACTIVITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; WHOLE PRASUGREL TABLET; BLOOD; MIDDLE AGED; ST ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION;

FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2Y12; ST ELEVATION MYOCARDIAL INFARCTION; TABLETS;

EID: 84961262611     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.02.045     Document Type: Article

References (30)

1. F. Franchi, and D.J. Angiolillo Novel antiplatelet agents in acute coronary syndrome Nat Rev Cardiol 12 2015 30 47
2. A.D. Michelson, A.L. Frelinger 3rd, E. Braunwald, and et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur Heart J 30 2009 1753 1763
3. S.D. Wiviott, E. Braunwald, C.H. McCabe, and et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
4. G. Montalescot, S.D. Wiviott, E. Braunwald, and et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
5. J.A. Udell, E. Braunwald, E.M. Antman, S.A. Murphy, G. Montalescot, and S.D. Wiviott Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38) J Am Coll Cardiol Intv 7 2014 604 612
6. M.W. Sherwood, S.D. Wiviott, S.A. Peng, and et al. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry J Am Heart Assoc 3 2014 e000849
7. M. Valgimigli, M. Tebaldi, G. Campo, and et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with STsegment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial J Am Coll Cardiol Intv 5 2012 268 277
8. D. Alexopoulos, I. Xanthopoulou, V. Gkizas, and et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
9. G. Parodi, R. Valenti, B. Bellandi, and et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) Primary PCI Study J Am Coll Cardiol 61 2013 1601 1606
10. F. Franchi, F. Rollini, J.R. Cho, and et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation J Am Coll Cardiol Intv 8 2015 1457 1467
11. P.G. Steg, A. van 't Hof, C.W. Hamm, and et al. Bivalirudin started during emergency transport for primary PCI N Engl J Med 369 2013 2207 2217
12. A.A. Heestermans, J.W. van Werkum, D. Taubert, and et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction Thromb Res 122 2008 776 781
13. D. Alexopoulos, V. Gkizas, S. Patsilinakos, and et al. Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI J Am Coll Cardiol 62 2013 940 941
14. G. Parodi, B. Bellandi, R. Valenti, and et al. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study Am Heart J 167 2014 909 914
15. D. Alexopoulos, G. Makris, I. Xanthopoulou, and et al. Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: pharmacodynamic study Circ Cardiovasc Interv 7 2014 233 239
16. G. Parodi, I. Xanthopoulou, B. Bellandi, and et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study J Am Coll Cardiol 65 2015 511 512
17. D. Alexopoulos, N. Barampoutis, V. Gkizas, and et al. Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic/pharmacodynamic study Clin Pharmacokinet 55 2016 359 367
18. N.A. Farid, M. McIntosh, F. Garofolo, and et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry Rapid Commun Mass Spectrom 21 2007 169 179
19. D.J. Angiolillo, J.A. Jakubowski, J.L. Ferreiro, and et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease J Am Coll Cardiol 64 2014 1005 1014
20. U.S. Tantry, L. Bonello, D. Aradi, and et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2273
21. L. Bonello, M. Laine, L. Camoin-Jau, and et al. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in non-ST elevation acute coronary syndrome Thromb Haemost 114 2015 702 707
22. G. Parodi, B. Bellandi, I. Xanthopoulou, and et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention Circ Cardiovasc Interv 8 2014 e001593
23. J.G. Diodati, J.F. Saucedo, J.K. French, and et al. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial Circ Cardiovasc Interv 6 2013 567 574
24. G. Montalescot, A.W. van 't Hof, F. Lapostolle, and et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction N Engl J Med 371 2014 1016 1027
25. D.J. Angiolillo, D.J. Schneider, D.L. Bhatt, and et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials J Thromb Thrombolysis 34 2012 44 55
26. M.U. Zafar, M.E. Farkouh, V. Fuster, and J.H. Chesebro Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets J Interv Cardiol 22 2009 385 389
27. R. Teng, G. Carlson, and J. Hsia An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers Int J Clin Pharmacol Ther 53 2015 182 189
28. J. Kubica, P. Adamski, M. Ostrowska, and et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial Eur Heart J 37 2016 245 252
29. E.L. Hobl, B. Reiter, C. Schoergenhofer, and et al. Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers Clin Res Cardiol 105 2016 349 355
30. P.G. Steg, D.L. Bhatt, C.W. Hamm, and et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data Lancet 382 2013 1981 1992